http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1384887-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5712b4838bdb16ebbc41121239e165b9
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
filingDate 1971-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1975-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-1384887-A
titleOfInvention Sustained release pharmaceutical tablet
abstract 1384887 Sustained release medicament BEECHAM GROUP Ltd 8 Aug 1972 [4 Sept 1971] 41337/71 Heading A5B A pharmaceutical sustained release tablet comprises a mixture of 1-15% w/w medicament which is 1-25% w/w soluble in water and/or gastric juice at 37‹C, 1-15% w/w of a substantially insoluble resin and 50-98% of a slightly soluble, inert, inorganic filler which is 0-3% w/w soluble in water or gastric juice at 37‹C. Up to 3% w/w conventional tableting excipients may also be present. Suitable resins include methacrylate copolymers, cellulose esters (including celullose acetate phthalate), polyvinyl acetate and its copolymers, and styrene/maleic anhydride copolymers. Suitable inert, inorganic fillers are CaSO 4 . 2H 2 O, BaSO 4 , CaHPO 4 , magnesium pyrophosphate and tribasic magnesium phosphate. Medicaments mentioned include; metoclopramide, fenfluoramine, sodium phenobarbitone, ephedrine and prednisone. Manufacture may be by mixing a slurry of the medicament, filler, resin and optional ingredients, drying and grinding the mixture and compressing the powder into tablets.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1207852-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1207852-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4917900-A
priorityDate 1971-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7501
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9294
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449207510
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID122213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533988
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453738556
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448969875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53627474
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505506
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456653168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24439
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492792
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23674889
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3337
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454134701

Total number of triples: 38.